ZYBTNasdaqPharmaceutical Preparations
Zhengye Biotechnology Holding Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026
$1.45+0.05 (+3.57%)
Close on Oct 19, 2026
Zhengye Biotechnology Holding Ltd revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Swine vaccines [Member] | CN¥90.14M | CN¥157.79M | CN¥188.92M | CN¥235.61M | 77.5% | -42.9% |
| Distribution network [Member] | CN¥61.50M | CN¥59.85M | CN¥49.62M | CN¥47.85M | 52.9% | +2.8% |
| Direct sales channel [Member] | CN¥51.90M | CN¥121.77M | CN¥159.53M | CN¥207.32M | 44.6% | -57.4% |
| Other vaccines [Member] | CN¥13.74M | CN¥13.06M | CN¥7.30M | CN¥8.29M | 11.8% | +5.2% |
| Poultry vaccines [Member] | CN¥12.48M | CN¥15.51M | CN¥15.43M | CN¥16.37M | 10.7% | -19.5% |
| Government tender and procurement [Member] | CN¥2.96M | CN¥4.73M | CN¥2.50M | CN¥5.10M | 2.5% | -37.3% |
By region
From the segment and revenue-disaggregation notes of Zhengye Biotechnology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.